HbA1c over 6-year follow-up and proportion of patients (%) per annum experiencing major hypoglycemic episodes (requiring third party or medical assistance)
| Allocation . | HbA1c . | Major hypoglycemic episodes . | |||
|---|---|---|---|---|---|
| Median (IQR) (%) . | P versus conventional glucose control policy . | P versus insulin alone . | % (95% CI) patients per annum . | P value versus insulin alone . | |
| Conventional glucose control policy | 7.6 (6.8–8.7) | 0 | |||
| Intensive glucose policy control | |||||
| Insulin alone | 7.1 (6.2–8.0) | <0.00001 | 3.4 (2.2–4.5) | ||
| Sulfonylurea (± insulin) | 6.6 (6.0–7.6) | <0.00001 | 0.0066 | 1.6 (0.9–2.2) | 0.0033 |
| Chlorpropamide (± insulin) | 6.6 (5.9–7.6) | <0.00001 | 0.010 | 1.8 (0.8–2.7) | 0.044 |
| Glipizide (± insulin) | 6.7 (6.1–7.6) | <0.00001 | 0.048 | 1.4 (0.6–2.2) | 0.0076 |
| Allocation . | HbA1c . | Major hypoglycemic episodes . | |||
|---|---|---|---|---|---|
| Median (IQR) (%) . | P versus conventional glucose control policy . | P versus insulin alone . | % (95% CI) patients per annum . | P value versus insulin alone . | |
| Conventional glucose control policy | 7.6 (6.8–8.7) | 0 | |||
| Intensive glucose policy control | |||||
| Insulin alone | 7.1 (6.2–8.0) | <0.00001 | 3.4 (2.2–4.5) | ||
| Sulfonylurea (± insulin) | 6.6 (6.0–7.6) | <0.00001 | 0.0066 | 1.6 (0.9–2.2) | 0.0033 |
| Chlorpropamide (± insulin) | 6.6 (5.9–7.6) | <0.00001 | 0.010 | 1.8 (0.8–2.7) | 0.044 |
| Glipizide (± insulin) | 6.7 (6.1–7.6) | <0.00001 | 0.048 | 1.4 (0.6–2.2) | 0.0076 |